James Chalmers, ERS 2020 – Bresocatib for Non-Cystic Fibrosis Bronchiectasis

We caught up with Professor James Chalmers (University of Dundee, Dundee, Scotland, UK) to discuss the recent phase 2, WILLOW clinical trial (NCT03218917), its results and what the future holds for bresocatib in the treatment of non-cystic fibrosis bronchiectasis. 

Questions

1. Could you please give us a brief overview of non-cystic fibrosis bronchiectasis, its prevalence and the unmet needs in its treatment? (0:08)
2. Could you tell us a little about brensocatib and its mechanism of action? (1:08)
3. What were the aims and design of the WILLOW clinical trial? (2:06)
4. What were the major efficacy and safety findings of the study? (2:50)
5. What will be the next step in the clinical development of brensocatib? (4:19)

Speakers Disclosure: Prof. James Chalmers has received research grants from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Pfizer, Grifols, Bayer AG, Polyphor and Insmed; and received consultancy, congress travel or speaker fees from GlaxoSmithKline, Bayer Healthcare, Aradigm Corporation, Grifols, Pfizer, Boehringer Ingelheim, Napp and Insmed.

Support: Interview and filming supported by Touch Medical Media.  

Filmed in coverage of the ERS International Congress Congress 2020.